Clinical Trial Update: Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating lenalidomide with sintilimab for relapsed/refractory NK/T-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nk T-cell Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Sintilimab (sintilimab)

Snippet

Sponsor: Beijing Tongren Hospital | Conditions: NK/T Cell Lymphoma Nos | Phase 2 | Status: UNKNOWN